Since you brought up Abarelix Depot, it’s amusing that AMGN paid six times as much in up-front cash ($100M) to license the drug from Praecis as GSK paid eight years later to acquire the entire company ($15M net of cash on hand).
Here are some entries from the PCRS archive on this board:
#msg-4741324 Praecis pulls all sales guidance for Plenaxis #msg-6263118 Management delusional on CC #msg-6418215 Another pathetic CC (re layoff announcement) #msg-7922700 German approval (oh, by the way, Schering AG pulled out) #msg-11669204 Plenaxis R.I.P.
p.s. As you probably know, Praecis was one of David Miler’s early picks.
Market Data 
Markets 
AI
